Analysis of factors associated with the development of myelofibrosis in polycythemia vera and essential thrombocythemia patients: a single-center experience

Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood J Am Soc Hematol 110(4):1092–1097 Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405 Cervantes F, Pereira A (2012) Prognostication in primary myelofibrosis. Curr Hematol Malig Rep 7(1):43–49. https://doi.org/10.1007/s11899-011-0102-1 Tefferi A (2003) The forgotten myeloproliferative disorder: myeloid metaplasia. Oncologist 8(3):225–231 Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S et al (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22(2):437–438. https://doi.org/10.1038/sj.leu.2404914 Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D et al (2008) Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 93(11):1645–1651. https://doi.org/10.3324/haematol.13346 Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M et al (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117(10):755–761. https://doi.org/10.1016/j.amjmed.2004.06.032 Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L et al (2014) Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 124(16):2507–2513. https://doi.org/10.1182/blood-2014-05-579136 (quiz 615) Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S et al (2007) The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer 109(1):68–76. https://doi.org/10.1002/cncr.22365 Boiocchi L, Mathew S, Gianelli U, Iurlo A, Radice T, Barouk-Fox S, et al. Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage. Modern Pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2013;26(12):1577–85. https://doi.org/10.1038/modpathol.2013.109. Tefferi A, Thiele J, Vardiman JW (2009) The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 115(17):3842–3847. https://doi.org/10.1002/cncr.24440 Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M et al (2011) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29(6):761 Barosi G (1999) Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol: Official J Am Soc Clin Oncol 17(9):2954–2970. https://doi.org/10.1200/jco.1999.17.9.2954 Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A (2006) Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 81(2):159–166. https://doi.org/10.4065/81.2.159 Cervantes F, Alvarez-Larrán A, Talarn C, Gómez M, Montserrat E (2002) Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol 118(3):786–790. https://doi.org/10.1046/j.1365-2141.2002.03688.x Passamonti F, Rumi E, Caramella M, Elena C, Arcaini L, Boveri E et al (2008) A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 111(7):3383–3387. https://doi.org/10.1182/blood-2007-11-121434 Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379–2390. https://doi.org/10.1056/NEJMoa1311347 Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369(25):2391–2405. https://doi.org/10.1056/NEJMoa1312542 Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L et al (2010) A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 24(9):1574–1579. https://doi.org/10.1038/leu.2010.148 Spivak JL (2017) Myeloproliferative neoplasms. N Engl J Med 376(22):2168–2181. https://doi.org/10.1056/NEJMra1406186 Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Randi ML et al (2012) Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood 119(10):2239–2241. https://doi.org/10.1182/blood-2011-11-393819 Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol: Official J Am Soc Clin Oncol 23(10):2224–2232. https://doi.org/10.1200/jco.2005.07.062 Mercan R, Bitik B, Tufan A, Bozbulut UB, Atas N, Ozturk MA et al (2016) The association between neutrophil/lymphocyte ratio and disease activity in rheumatoid arthritis and ankylosing spondylitis. J Clin Lab Anal 30(5):597–601. https://doi.org/10.1002/jcla.21908 Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ (2012) A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 107(4):695–699. https://doi.org/10.1038/bjc.2012.292 Romano A, Palandri F, Masarova L, Bonifacio M, Polverelli N, Elli EM et al (2018) Prognostic role of neutrophil to lymphocyte ratio (NLR) in myelofibrosis patients treated with ruxolitinib: a multi-center experience. Blood 132(Supplenent 1):4303. https://doi.org/10.1182/blood-2018-99-116418 Kisseleva T, Brenner DA (2008) Mechanisms of fibrogenesis. Exp Biol Med 233(2):109–122 Wong KL, Yeap WH, Tai JJ, Ong SM, Dang TM, Wong SC (2012) The three human monocyte subsets: implications for health and disease. Immunol Res 53(1–3):41–57. https://doi.org/10.1007/s12026-012-8297-3 Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M et al (2011) Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol: Official J Am Soc Clin Oncol 29(23):3179–3184. https://doi.org/10.1200/jco.2010.34.5298 Vener C, Novembrino C, Catena FB, Fracchiolla NS, Gianelli U, Savi F et al (2010) Oxidative stress is increased in primary and post-polycythemia vera myelofibrosis. Exp Hematol 38(11):1058–1065. https://doi.org/10.1016/j.exphem.2010.07.005 Gaman AM, Moisa C, Diaconu CC, Gaman MA (2019) Crosstalk between oxidative stress, chronic inflammation and disease progression in essential thrombocythemia. Rev Chim 70(10):3486–3489 Ellis JT, Peterson P, Geller SA, Rappaport H (1986) Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin Hematol 23(2):144–155 Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895–2901. https://doi.org/10.1182/blood-2008-07-170449 Georgii A, Buhr T, Buesche G, Kreft A, Choritz H (1996) Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk Lymphoma 22(sup1):15–29 Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F et al (2017) Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood J Am Soc Hematol 129(24):3227–3236 Tefferi A (2013) Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 88(2):141–150 Campbell PJ, Bareford D, Erber WN, Wilkins BS, Wright P, Buck G et al (2009) Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol: Official J Am Soc Clin Oncol 27(18):2991–2999. https://doi.org/10.1200/jco.2008.20.3174 Cervantes F, Hernandez-Boluda JC, Villamor N, Serra A, Montserrat E (2000) Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis. Eur J Haematol 65(2):104–108. https://doi.org/10.1034/j.1600-0609.2000.90262.x Hernandez-Boluda JC, Pereira A, Gomez M, Boque C, Ferrer-Marin F, Raya JM et al (2014) The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis. Haematologica 99(4):e55–e57. https://doi.org/10.3324/haematol.2013.101733 Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T et al (2017) Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res 59:110–116. https://doi.org/10.1016/j.leukres.2017.06.001 Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L et al (2016) Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 30(8):1701–1707. https://doi.org/10.1038/leu.2016.148 Cervantes F, Pereira A (2017) Does ruxolitinib prolong the survival of patients with myelofibrosis? Blood 129(7):832–837. https://doi.org/10.1182/blood-2016-11-731604